Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917629 | 0.74 | — | — | |
| SCHEMBL29649161 | 0.69 | ADRB1 (0.34) | ALDH1A1LMNAADRB1EPHX2HTR3E | |
| SCHEMBL517802 | 0.68 | ADRB1 (0.37) | ALDH1A1LMNAADRB1EPHX2HTR3E | |
| SCHEMBL28080518 | 0.67 | ALDH1A1 (0.67) | ALDH1A1LMNAADRB1EPHX2HTR3E | |
| SCHEMBL26646496 | 0.66 | ADRB1 (0.35) | ALDH1A1LMNAADRB1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL12818396 | 0.66 | ALDH1A1 (0.37) | ALDH1A1LMNAADRB1HTR3EHTR3B | |
| Hydrazine SCHEMBL27569857 | 0.64 | ADRB1 (0.34) | ALDH1A1LMNAADRB1HTR3EHTR3B | |
| SCHEMBL28311781 | 0.64 | ADRB1 (0.34) | ALDH1A1LMNAADRB1HTR3EHTR3B | |
| SCHEMBL15313178 | 0.64 | ADRB1 (0.34) | ALDH1A1LMNAADRB1HTR3EHTR3B | |
| SCHEMBL1219179 | 0.62 | ADRB1 (0.31) | ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981131-B2 | Tricyclic compounds for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2015-03-17 | — | — | US | disclosed |
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2011-01-13 | — | — | US | disclosed |
| WO-2009016565-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL1R1, IL1B, IL1A | ALDH1A1 1115/4885LMNA 1971/4885ADRB1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.